Soligenix Inc. published a shareholder letter from President and Chief Executive Officer Dr. Christopher J. Schaber on February 12, 2026. The letter provides an update on recent progress and outlines upcoming milestones for 2026. The company is evaluating potential strategic options, including partnership and merger and acquisition opportunities. Efforts continue toward partnership in ex-U.S. markets and discussions are ongoing with potential partners. The company is advancing toward the completion of the FLASH2 confirmatory trial and is pursuing marketing authorizations for HyBryte™ worldwide. Additional cutaneous indications for HyBryte™ are also under evaluation. The full letter can be accessed through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-014267), on February 12, 2026, and is solely responsible for the information contained therein.